CRBP Corbus Pharmaceuticals Holdings Inc

Price (delayed)

$58.06

Market cap

$620.47M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.94

Enterprise value

$622.98M

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company's lead product candidate, lenabasum, is ...

Highlights

The quick ratio rose by 49% YoY

Corbus Pharmaceuticals Holdings's EPS has increased by 43% YoY and by 33% QoQ

Sector: Healthcare

Industry: Biotechnology

Website: http://www.corbuspharma.com

Peers: ESPR VRTX AKBA

Key stats

What are the main financial stats of CRBP

Market

Shares outstanding

10.69M

Market cap

$620.47M

Enterprise value

$622.98M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

6.28

Price to sales (P/S)

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

Earnings

Revenue

EBIT

-$31.33M

EBITDA

-$30.72M

Free cash flow

-$28.95M

Per share

EPS

-$6.94

Free cash flow per share

-$3.48

Book value per share

$9.24

Revenue per share

TBVPS

$15.13

Balance sheet

Total assets

$125.74M

Total liabilities

$28.78M

Debt

$17.29M

Equity

$96.97M

Working capital

$95.77M

Liquidity

Debt to equity

0.18

Current ratio

4.69

Quick ratio

4.66

Net debt/EBITDA

-0.08

Margins

EBITDA margin

N/A

Gross margin

N/A

Net margin

N/A

Operating margin

N/A

Efficiency

Return on assets

-57.7%

Return on equity

-135.2%

Return on invested capital

-76.9%

Return on capital employed

-31.4%

Return on sales

N/A

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

CRBP stock price

How has the Corbus Pharmaceuticals Holdings stock price performed over time

Intraday

4.71%

1 week

0.1%

1 month

33.5%

1 year

767.86%

YTD

861.26%

QTD

28.31%

Financial performance

How have Corbus Pharmaceuticals Holdings's revenue and profit performed over time

Revenue

Gross profit

Operating income

-$37.4M

Net income

-$33.76M

Gross margin

N/A

Net margin

N/A

Corbus Pharmaceuticals Holdings's net income has increased by 33% YoY and by 24% from the previous quarter

The operating income is up by 23% year-on-year and by 17% since the previous quarter

Growth

What is Corbus Pharmaceuticals Holdings's growth rate over time

Valuation

What is Corbus Pharmaceuticals Holdings stock price valuation

P/E

N/A

P/B

6.28

P/S

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

Corbus Pharmaceuticals Holdings's EPS has increased by 43% YoY and by 33% QoQ

CRBP's P/B is 49% below its 5-year quarterly average of 12.3

Efficiency

How efficient is Corbus Pharmaceuticals Holdings business performance

The ROE has soared by 85% QoQ and by 6% YoY

The ROA has increased by 48% from the previous quarter and by 22% YoY

CRBP's return on invested capital is up by 47% since the previous quarter

Dividends

What is CRBP's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CRBP.

Financial health

How did Corbus Pharmaceuticals Holdings financials performed over time

Corbus Pharmaceuticals Holdings's total assets has surged by 143% YoY

The quick ratio rose by 49% YoY

CRBP's debt is 82% smaller than its equity

CRBP's debt to equity has soared by 106% since the previous quarter but it has dropped by 88% year-on-year

CRBP's debt is down by 30% year-on-year and by 17% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.